Nestlé is buying the maker of a peanut allergy drug for $2.6 billion. Aimmune (AIMT) is a California-based biotechnology firm that received USDA approval for Palforzia, a drug designed to help children build up their immune response to peanuts, CNN reports. Nestlé, the world’s largest food and beverage company, has now made multiple investments into researching and developing food allergy-related products via its Nestlé Health Sciences division.
Grist, an award-winning, nonprofit media organization dedicated to highlighting climate solutions and uncovering environmental injustices,…
Every year, California dairy farms emit hundreds of thousands of tons of the potent greenhouse…
Highway 7 runs north-south through western Washington, carving its way through a landscape sparsely dotted…
One of the greatest pleasures I had as a child growing up in the Chicago…
Undocumented immigrants experience food insecurity at much higher rates than other populations, yet they are…
Writer Charlotte Druckman and editor Rebecca Flint Marx are both Jewish journalists living in New…